Loading organizations...
Founded in 2002 and based in Redwood City, California, Codexis is a publicly traded biotechnology and enzyme engineering company that develops proprietary biocatalysts and manufacturing platforms for therapeutic development. Utilizing its CodeEvolver and ECO Synthesis platforms, the enterprise creates high-performance enzymes designed to enable scalable and sustainable production processes for RNAi therapeutics, diagnostics, and small molecule manufacturing. The firm operates with a workforce of 188 employees and generated over 59 million dollars in total revenue during the 2024 fiscal year. Codexis generates revenue primarily through licensing agreements and manufacturing platform solutions, securing strategic partnerships with major pharmaceutical and biotechnology corporations such as Pfizer and Aldevron LLC. The executive team is led by Chief Executive Officer Stephen Dilly, who previously served as the head of Sierra Oncology prior to its nearly two billion dollar acquisition by GlaxoSmithKline.
Codexis, Inc. has raised $37.0M across 1 funding round.
Key people at Codexis, Inc..
Codexis, Inc. has raised $37.0M in total across 1 funding round.
Codexis, Inc. has raised $37.0M in total across 1 funding round.
Codexis, Inc.'s investors include M34 Capital.
Codexis, Inc. is a biotechnology company specializing in protein engineering to develop high-performance enzymes primarily for pharmaceutical, food, and medical applications. It builds enzyme-based solutions that enable faster, cleaner, and scalable manufacturing processes for complex therapeutics such as RNA medicines and pharmaceutical biocatalysis. Codexis serves pharmaceutical companies and life sciences sectors by solving challenges related to drug manufacturing efficiency, sustainability, and scalability, leveraging proprietary platforms like CodeEvolver® that combine machine learning with directed enzyme evolution[1][2][3].
Founded in 2002 and headquartered in Redwood City, California, Codexis went public in 2010. The company emerged from pioneering work in enzyme engineering, gaining early recognition with two U.S. EPA Presidential Green Chemistry Challenge Awards for its contributions to drug synthesis. Its growth has been marked by strategic partnerships with major industry players like Merck, Nestlé Health Sciences, Tate & Lyle, and Takeda Pharmaceutical, expanding its impact from pharmaceuticals to nutrition and gene therapies. Key milestones include acquiring Maxygen’s MolecularBreeding technology and launching advanced RNA manufacturing platforms[1][2].
Codexis rides the wave of increasing demand for sustainable and efficient biomanufacturing in pharmaceuticals, especially RNA therapeutics and gene therapies, which require novel manufacturing approaches. The timing is critical as the biotech industry shifts from traditional chemical synthesis to biologically driven processes that reduce environmental impact and improve scalability. Codexis’s enzyme engineering platforms position it as a key enabler of next-generation therapeutic manufacturing, influencing the broader ecosystem by setting new standards for speed, sustainability, and precision in drug production[1][2][3].
Looking ahead, Codexis is poised to expand its leadership in enzyme-enabled therapeutic manufacturing, particularly in RNA and gene therapy sectors, which are expected to grow rapidly. Continued innovation in AI-driven enzyme design and scalable manufacturing platforms will likely drive faster drug development timelines and greener production methods. As the biotech industry increasingly embraces enzymatic solutions, Codexis’s influence will deepen, potentially reshaping pharmaceutical manufacturing paradigms and accelerating the availability of advanced therapies worldwide[2][3].
Codexis, Inc. has raised $37.0M across 1 funding round. Most recently, it raised $37.0M Codexis - Series D in August 2006.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2006 | $37M Series D | — | M34 Capital | Announced |
Key people at Codexis, Inc..
